iPSC Preparation and Epigenetic Memory: Does the Tissue Origin Matter?

Scesa, Giuseppe; Adami, Raffaella; Bottai, Daniele

doi:10.3390/cells10061470

Cited by 50 publications

(47 citation statements)

References 127 publications

(210 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thanks to the abovementioned advantages, iPSC technology may be implemented as an alternative to autologous grafting, by which the patient-specific somatic cells are reprogramed into MSCs/osteoprogenitor cells, and seeded on an appropriate scaffold, and treated with bioactive molecules [50]. It is assumed that, in the case of dental tissue regeneration, the generation of iPSCs from dental tissue may be more beneficial than other tissue sources because of probable epigenetic memory maintenance of the source tissue [9,51]. In comparison with dental tissue-derived stem cells, dental tissue-derived iPSCs are more proliferative in vitro and its regenerative ability can be more easily reproduced [52].…”

Section: Osteogenic Potential Of Ipscs In Dental Tissue Regenerationmentioning

confidence: 99%

Stem Cells and Their Derivatives—Implications for Alveolar Bone Regeneration: A Comprehensive Review

Hollý

Klein

Mazreku

et al. 2021

IJMS

View full text Add to dashboard Cite

Oral and craniofacial bone defects caused by congenital disease or trauma are widespread. In the case of severe alveolar bone defect, autologous bone grafting has been considered a “gold standard”; however, the procedure has several disadvantages, including limited supply, resorption, donor site morbidity, deformity, infection, and bone graft rejection. In the last few decades, bone tissue engineering combined with stem cell-based therapy may represent a possible alternative to current bone augmentation techniques. The number of studies investigating different cell-based bone tissue engineering methods to reconstruct alveolar bone damage is rapidly rising. As an interdisciplinary field, bone tissue engineering combines the use of osteogenic cells (stem cells/progenitor cells), bioactive molecules, and biocompatible scaffolds, whereas stem cells play a pivotal role. Therefore, our work highlights the osteogenic potential of various dental tissue-derived stem cells and induced pluripotent stem cells (iPSCs), the progress in differentiation techniques of iPSCs into osteoprogenitor cells, and the efforts that have been made to fabricate the most suitable and biocompatible scaffold material with osteoinductive properties for successful bone graft generation. Moreover, we discuss the application of stem cell-derived exosomes as a compelling new form of “stem-cell free” therapy.

show abstract

Section: Osteogenic Potential Of Ipscs In Dental Tissue Regenerationmentioning

confidence: 99%

Stem Cells and Their Derivatives—Implications for Alveolar Bone Regeneration: A Comprehensive Review

Hollý

Klein

Mazreku

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Analysis of disease-specific hiPSC-derived-CMs compared to wild-type hiPSC-derived-CMs prepared from healthy donor cells as controls can lead to unreliable results because the genetic and epigenetic background of the cells is largely unknown [ 165 , 166 ]. Even when control cells from non-diseased individuals in the same family (first-degree relatives) are used, the patients from whom the disease cells are derived share only ≈50% of the genome [ 166 , 167 , 168 ]. The importance of having an isogenic cell line increases the chance of identifying the role of a particular mutation in the disease and circumventing heterogeneity between patients [ 169 ].…”

Section: Applications Of Genome Editing Technology In Hipscmentioning

confidence: 99%

Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform—A Cardiac Perspective

Bekhite

Schulze

2021

Cells

View full text Add to dashboard Cite

A comprehensive understanding of the pathophysiology and cellular responses to drugs in human heart disease is limited by species differences between humans and experimental animals. In addition, isolation of human cardiomyocytes (CMs) is complicated because cells obtained by biopsy do not proliferate to provide sufficient numbers of cells for preclinical studies in vitro. Interestingly, the discovery of human-induced pluripotent stem cell (hiPSC) has opened up the possibility of generating and studying heart disease in a culture dish. The combination of reprogramming and genome editing technologies to generate a broad spectrum of human heart diseases in vitro offers a great opportunity to elucidate gene function and mechanisms. However, to exploit the potential applications of hiPSC-derived-CMs for drug testing and studying adult-onset cardiac disease, a full functional characterization of maturation and metabolic traits is required. In this review, we focus on methods to reprogram somatic cells into hiPSC and the solutions for overcome immaturity of the hiPSC-derived-CMs to mimic the structure and physiological properties of the adult human CMs to accurately model disease and test drug safety. Finally, we discuss how to improve the culture, differentiation, and purification of CMs to obtain sufficient numbers of desired types of hiPSC-derived-CMs for disease modeling and drug development platform.

show abstract

“…Mutations can indeed alter signaling pathways and give tumor-initiating cells a stemness, but it cannot be ruled out that HCC with a stem cell phenotype can directly inherit the epigenetic status of the above-mentioned signaling pathways from the normal corresponding initial stem cells. In addition, although somatic cells can be reprogrammed into pluripotent ES-like cells by ectopic expression of transcription factors such as Oct4, Sox2, Klf4, and C-MyC (OSKM), 46 whether “dedifferentiation” can promote individual tumorigenesis without any additional manipulation needs to be supported by reliable evidence.…”

Section: Mainmentioning

confidence: 99%

Re-Recognizing the Cellular Origin of the Primary Epithelial Tumors of the Liver

Ji-liang¹,

Zhu²,

Yin³

et al. 2021

JHC

View full text Add to dashboard Cite

The primary epithelial tumors of the liver (PETL) are composed of a series of heterogeneous tumors. Although the classification of PETLs has been updated several times by the World Health Organization, the cellular origins of some tumors in this family remain to be precisely depicted. In addition, certain tumors in different categories have similar histology, molecular phenotypes and biological characteristics, suggesting that they may have the same cellular origin. In this work, a narrative review method was adopted to review the relevant papers. By comparing the expression profiles of biomarkers of liver epithelium at different lineages and stages of differentiation, the cells-of-origin of some major members of the PETL family were reassessed. We propose that 1) hepatic adenomas, hepatocellular carcinomas (HCCs) and pure fetal hepatoblastomas (HBs) share the same spectrum in their cellular origin including the hepatocytic-committed progenitors (HCP) and their differentiated descendants. 2) Bile duct adenomas, peribiliary cysts and intrahepatic cholangiocellular carcinomas (ICCs) can share the same spectrum in their cellular origin including the cholangiocytic-committed progenitors (CCP) and their differentiated descendants. 3) The cells-of-origin of embryonal HBs include liver stem cells (LSCs), hepatoblasts, and transitional cells between them. Embryonal HB with small cell element, small cell undifferentiated HB and small cell neuroendocrine carcinoma of the liver can have the same or similar cellsof-origin from LSC. Embryonal HB lacking the small cell component of the LSC phenotype and presenting both hepatocytic and bile duct/ductule components may originate from actual hepatoblasts/hepatic progenitor cells (HPCs) as the combined HCC-ICC does. 4) Teratoid hepatoblastoma and mixed epithelial/mesenchymal HBs can be derived from the LSCs or even less committed extrahepatic pluripotent stem cell. 5) Many members of the PETLs family, including those derived from LSCs, hepatoblasts/HPCs, early HCPs and CCPs, have neuroendocrine potentiality. Except for those primary hepatic neuroendocrine tumor (PHNET) exhibit hepatocytic and/or cholangiocytic phenotypes, other PHNETs subtype may be derived from the descendants of LSC that differentiate towards the upper digestive tract, pancreas or other lineages.

show abstract

iPSC Preparation and Epigenetic Memory: Does the Tissue Origin Matter?

Cited by 50 publications

References 127 publications

Stem Cells and Their Derivatives—Implications for Alveolar Bone Regeneration: A Comprehensive Review

Stem Cells and Their Derivatives—Implications for Alveolar Bone Regeneration: A Comprehensive Review

Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform—A Cardiac Perspective

Re-Recognizing the Cellular Origin of the Primary Epithelial Tumors of the Liver

Contact Info

Product

Resources

About